BMS-986488

Phase 1Small molecule

Bristol-Myers Squibb

BMS-986488 is one of 4 small molecule programs targeting Advanced Malignant Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant TumorsRecruiting

Advanced Malignant TumorsPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Advanced Malignant Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 1

1 2

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 3

Erbitux

IImclone

Phase 1

1 4

BMS-986488

Bristol-Myers Squibb

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Advanced Malignant Tumors

NCT06764771

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06764771·437 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986488. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986488 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986488. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

BMS-986488

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced Malignant Tumors1 trial

References

Drug Info

Quick Facts

Related News